CN Patent
CN107260672A — 包含纳洛酮的鼻内药物剂型
Assigned to Euro Celtique SA · Expires 2017-10-20 · 9y expired
What this patent protects
本申请涉及包含纳洛酮的鼻内药物剂型。本发明涉及鼻内药物剂型,其包含剂量单元,所述剂量单元包含溶于≤250μl体积施用流体中的相当于≥0.5mg盐酸纳洛酮之量的纳洛酮或其可药用盐。本发明还涉及这样的鼻内药物剂型,其用于治疗阿片样物质过量给药和/或其至少一种症状。
USPTO Abstract
本申请涉及包含纳洛酮的鼻内药物剂型。本发明涉及鼻内药物剂型,其包含剂量单元,所述剂量单元包含溶于≤250μl体积施用流体中的相当于≥0.5mg盐酸纳洛酮之量的纳洛酮或其可药用盐。本发明还涉及这样的鼻内药物剂型,其用于治疗阿片样物质过量给药和/或其至少一种症状。
Drugs covered by this patent
- naloxone-hydrochloride (Naloxone Hydrochloride) · Pfizer Inc.
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.